Literature DB >> 10564094

Long-wavelength iodide-sensitive fluorescent indicators for measurement of functional CFTR expression in cells.

S Jayaraman1, L Teitler, B Skalski, A S Verkman.   

Abstract

Limitations of available indicators [such as 6-methoxy-N-(3-sulfopropyl)quinolinium (SPQ)] for measurement of intracellular Cl(-) are their relatively dim fluorescence and need for ultraviolet excitation. A series of long-wavelength polar fluorophores was screened to identify compounds with Cl(-) and/or I(-) sensitivity, bright fluorescence, low toxicity, uniform loading of cytoplasm with minimal leakage, and chemical stability in cells. The best compound found was 7-(beta-D-ribofuranosylamino)-pyrido[2, 1-h]-pteridin-11-ium-5-olate (LZQ). LZQ is brightly fluorescent with excitation and emission maxima at 400-470 and 490-560 nm, molar extinction 11,100 M(-1). cm(-1) (424 nm), and quantum yield 0.53. LZQ fluorescence is quenched by I(-) by a collisional mechanism (Stern-Volmer constant 60 M(-1)) and is not affected by other halides, nitrate, cations, or pH changes (pH 5-8). After LZQ loading into cytoplasm by hypotonic shock or overnight incubation, LZQ remained trapped in cells (leakage <3%/h). LZQ stained cytoplasm uniformly, remained chemically inert, did not bind to cytoplasmic components, and was photobleached by <1% during 1 h of continuous illumination. Cytoplasmic LZQ fluorescence was quenched selectively by I(-) (50% quenching at 38 mM I(-)). LZQ was used to measure forskolin-stimulated I(-)/Cl(-) and I(-)/NO(-)(3) exchange in cystic fibrosis transmembrane conductance regulator (CFTR)-expressing cell lines by fluorescence microscopy and microplate reader instrumentation using 96-well plates. The substantially improved optical and cellular properties of LZQ over existing indicators should permit the quantitative analysis of CFTR function in gene delivery trials and high-throughput screening of compounds for correction of the cystic fibrosis phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564094     DOI: 10.1152/ajpcell.1999.277.5.C1008

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

Review 1.  Acid-Base Basics.

Authors:  Michael F Romero; Adam J Rossano
Journal:  Semin Nephrol       Date:  2019-07       Impact factor: 5.299

Review 2.  Chloride transport modulators as drug candidates.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Am J Physiol Cell Physiol       Date:  2021-10-13       Impact factor: 4.249

3.  CFTR-mediated halide transport in phagosomes of human neutrophils.

Authors:  Richard G Painter; Luis Marrero; Gisele A Lombard; Vincent G Valentine; William M Nauseef; Guoshun Wang
Journal:  J Leukoc Biol       Date:  2010-01-20       Impact factor: 4.962

Review 4.  CFTR inhibitors.

Authors:  Alan S Verkman; David Synder; Lukmanee Tradtrantip; Jay R Thiagarajah; Marc O Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Authors:  Steven Molinski; Paul D W Eckford; Stan Pasyk; Saumel Ahmadi; Stephanie Chin; Christine E Bear
Journal:  Front Pharmacol       Date:  2012-09-26       Impact factor: 5.810

Review 6.  Advances in the development of novel compounds targeting cation-chloride cotransporter physiology.

Authors:  Eric Delpire
Journal:  Am J Physiol Cell Physiol       Date:  2020-12-23       Impact factor: 5.282

7.  Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.

Authors:  Daniela De Stefano; Valeria R Villella; Speranza Esposito; Antonella Tosco; Angela Sepe; Fabiola De Gregorio; Laura Salvadori; Rosa Grassia; Carlo A Leone; Giuseppe De Rosa; Maria C Maiuri; Massimo Pettoello-Mantovani; Stefano Guido; Anna Bossi; Anna Zolin; Andrea Venerando; Lorenzo A Pinna; Anil Mehta; Gianni Bona; Guido Kroemer; Luigi Maiuri; Valeria Raia
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

8.  Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells.

Authors:  Erika N Sutanto; Amelia Scaffidi; Luke W Garratt; Kevin Looi; Clara J Foo; Michela A Tessari; Richard A Janssen; David F Fischer; Stephen M Stick; Anthony Kicic
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

9.  A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

Authors:  A Tosco; F De Gregorio; S Esposito; D De Stefano; I Sana; E Ferrari; A Sepe; L Salvadori; P Buonpensiero; A Di Pasqua; R Grassia; C A Leone; S Guido; G De Rosa; S Lusa; G Bona; G Stoll; M C Maiuri; A Mehta; G Kroemer; L Maiuri; V Raia
Journal:  Cell Death Differ       Date:  2016-04-01       Impact factor: 15.828

10.  Mutation-Dependent Pathomechanisms Determine the Phenotype in the Bestrophinopathies.

Authors:  Anna-Lena Nachtigal; Andrea Milenkovic; Caroline Brandl; Heidi L Schulz; Lisa M J Duerr; Gabriele E Lang; Charlotte Reiff; Philipp Herrmann; Ulrich Kellner; Bernhard H F Weber
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.